Q2 2022
Released Jul 28, 2022, before the open
10-Q filed Aug 10, 2022, 38 days after period end · 0000078003-22-000094
Q2 2022 · 10-Q
Revenue$27.74B$27.74B +46.8% vs Q2 2021+8.1% vs Q1 2022
Net Income$9.91B$9.91B +78.1% vs Q2 2021+26.0% vs Q1 2022
EPS Diluted$1.73$1.73 +76.5% vs Q2 2021+26.3% vs Q1 2022
Operating Cash Flowderived$8,170,000,000−27.7%
Free Cash Flowderived$7,419,000,000−31.1%
Margins · derived
Net margin35.7%+6.3 pt vs Q2 2021
What the release said
The release
Same quarter
| Metric | Q2 2022 | Q2 2021 | Q2 2020 | Q2 2019 |
|---|---|---|---|---|
| Revenue | $27.74B | $18.90B | $9.86B | $13.26B |
| Net Income | $9.91B | $5.56B | $3.49B | $5.05B |
| EPS Diluted | $1.73 | $0.98 | $0.62 | $0.89 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pfizer Inc · CIK 78003 · Engraved from SEC EDGAR